Razvan Albu

Razvan Albu, PhD, Research Officer

Razvan (Raz for short) received his PhD in Biochemistry in 2012 from Jacobs University in Bremen, Germany, where he studied the target sequence recognition mechamism of bacterial the bacterial DNA methyltransferase CcrM, a critical component of the cell division cycle in alpha-proteobacteria. As a postdoctoral researcher at the University of British Columbia (Canada), he used mass spectrometry-based proteomics to study protein aggregates associated with neurodegenerative diseases. In September 2015, Razvan transitioned to the private sector, taking on a Research and Development role in the Department of Molecular Biology Applications at Applied Biological Materials, a biotech startup located in Vancouver, Canada. There he coordinated cloning efforts, designed new expression plasmids and helped design and establish a brand new lab facility for the department. It was here that Razvan attained in-depth knowledge of the cutting edge CRISPR/Cas9 technology, for which he established experimental pipelines for in-house services, oversaw QC of in-house produced Cas9 enzymes and added multiple new products and services. Razvan joined the Vector and Genome Editing Core facility in April 2019.